Pleural Effusion and Immunotherapy — What Actually Changes

Not on its own. Fluid around the lung does not by itself rule immunotherapy in or out. But most people with lung cancer in India are not candidates for it, and the reasons usually have nothing to do with the effusion. The biomarker report, the tumour type, autoimmune history and how well you are at diagnosis decide far more.

This is said first, and plainly, because lung cancer is the largest immunotherapy population in India and most of what families read online describes people who already cleared these hurdles. Being told that immunotherapy exists is not the same as being told it applies to you. At CION the eligibility question goes to the tumour board with the histology, the biomarker report and the current scan in front of it, before any plan is put to a family.

What the effusion does change: a pleural effusion with cancer cells in the fluid places non-small cell lung cancer at an advanced stage, so the plan is built around systemic treatment rather than surgery. It raises the priority of every new breathing symptom. And it can supply the tissue your biomarker report is run on.

Eligibility criteria as set out in NCCN and ESMO non-small cell lung cancer guidance; what may be prescribed in India is governed by CDSCO labelling. Ask your oncologist which criteria are being applied to you, in writing.

Yes, and it can mislead everyone. In the first weeks the fluid can increase, or a small new effusion can appear, while the treatment is in fact doing what it is meant to do. Immune cells moving into the tumour and the pleural lining cause inflammation, and inflammation makes fluid.

Where this goes wrong: an early scan showing more fluid gets reported as progression, a treatment that was working is stopped, and the family is told to prepare for a change of plan. That is the single most useful thing to know from this page. It is also why the opposite mistake matters just as much — a rising effusion in someone who is getting steadily worse is not explained away as inflammation. Genuine early inflammatory change is uncommon, and it is never a reason to continue treatment in a person who is deteriorating.

The rule our tumour board works to is simple. The decision to continue, pause or change is made on how you are, supported by the scan — not on the scan alone. If the two disagree, the scan is repeated after a short interval while symptoms are watched closely, and the reasoning is written down for you. Immune-specific response criteria such as iRECIST were developed by the research community for exactly this situation, and NCCN and ESMO guidance both acknowledge that early imaging in immunotherapy can be misread.

By draining it when it makes you breathless, and by treating the cancer underneath it. Fluid that causes no symptoms is usually watched, not drained. Fluid that keeps returning is controlled with a repeat procedure, a pleurodesis, or a drain you keep at home. Drainage relieves symptoms; it is not itself cancer treatment.

1. Confirm what the fluid is. The first drainage sends fluid to the laboratory to look for cancer cells. Ask at that point for a cell block to be made, so biomarker tests can be run on the same sample instead of needing another procedure.
2. Drain for symptoms, not for the scan. A small effusion that is not making you breathless is generally left alone and watched. Draining fluid that is causing no trouble adds risk without adding benefit.
3. Take large volumes off slowly. When a big effusion is drained, it is removed in stages rather than all at once, because emptying the space too quickly can cause chest pain, coughing and problems as the lung re-expands.
4. If it keeps coming back, change the method. Repeated needle drainage is reasonable a few times. Beyond that the options are a chest tube, a pleurodesis procedure that seals the space so fluid cannot re-collect, or an indwelling pleural catheter that stays in and is drained at home. Each suits a different situation, and the choice depends on how quickly fluid returns, whether the lung re-expands, and how much time you want to spend in hospital.
5. Keep treating the cancer. Where immunotherapy is working, controlling the fluid is a supportive step alongside it, not a replacement for it. Where the fluid is refilling quickly and you are getting worse, the systemic plan itself is reviewed.
6. Fit the procedure around the cycle, not the other way round. A drainage does not usually mean immunotherapy has to stop. A procedure may shift an infusion by a few days. Tell the day-care team before the cycle so bloods and timing are arranged once.

A practical note on who does what. At CION, immunotherapy is given as day care at our centres. Pleural procedures are carried out by a pulmonologist or a thoracic surgical team, and response-assessment imaging is coordinated for you at partner imaging centres rather than owned by us. Ask for the sequence in writing — which procedure, on which date, and which cycle it sits between — so that nobody is left arranging it on the morning of an infusion.

By the pattern, not by the symptom. Breathlessness is the same complaint in both. A recurring effusion usually builds over days to weeks and eases when fluid is drained. Immune pneumonitis often brings a new dry cough and falling oxygen levels, and drainage changes nothing. A chest X-ray or CT separates them quickly.

Pattern and management as described in NCCN and ESMO immune-related adverse event guidance. Never start, stop or adjust steroids yourself. If breathing is worse than last week, or a new dry cough has started, call 1800 202 8726 the same day; if breathing is severely difficult, go to the nearest emergency department now.

Often, yes. When enough tumour cells are recovered, the laboratory can prepare a cell block from the drained fluid and run PD-L1, EGFR, ALK and ROS1 on it. That matters when the lung tumour is awkward to biopsy. It does not always work — cell-poor fluid may need a repeat sample or a tissue biopsy instead.

Sample-adequacy and biomarker testing pathways as set out in NCCN and ESMO non-small cell lung cancer guidance, with Indian practice guided by ICMR consensus documents. The commonest avoidable problem we see in second opinions is a first drainage that was sent for cytology only, so every biomarker question then needed another procedure.

There are two bills, and they behave differently. Drainage is episodic — it costs what it costs each time it is needed. The systemic treatment repeats on a schedule and continues while it is working. All figures are indicative, as of August 2026, and change with the option selected, the centre and your scheme cover.

What actually drives the total:

• How often the fluid needs draining — a one-off procedure and a fluid that refills every fortnight are very different propositions.
• Which method is chosen — repeat needle drainage, a chest tube, a pleurodesis or an indwelling catheter each carry a different cost and a different number of hospital visits.
• Whether treatment is given as day care — immunotherapy at CION is day care, so there is no overnight stay for the infusion itself.
• Imaging — response-assessment scans are coordinated for you at partner imaging centres and quoted before the appointment.
• Laboratory work on the fluid — a cell block with several biomarker tests costs more than plain cytology, and usually saves a repeat procedure.
• Scheme and insurance cover — Aarogyasri, CGHS, ECHS, ESI and private insurance each handle the procedure and the systemic treatment differently, and ceilings change.

Six questions worth asking:

• Has the fluid been confirmed as malignant? Not every effusion in lung cancer contains cancer cells, and the answer changes the plan.
• Was a cell block made, and what was run on it? Ask for PD-L1, EGFR, ALK and ROS1 results, or an explanation of why they could not be done.
• Am I eligible for immunotherapy at all? Ask this directly. For many people the honest answer is no, and it is better heard early than after a costly detour.
• If the next scan shows more fluid, what happens? Ask whether a confirmation scan would be offered if you are otherwise well, and get the answer before the scan, not after it.
• What is the plan for the fluid itself? Repeat drainage, pleurodesis or a home catheter — and how many hospital visits each involves.
• Who do I call at 2am? Have one number written on the folder, and know which symptoms mean the emergency department instead.

If you are the family member coordinating this, carry one folder: the histopathology report, the fluid cytology and cell-block report, the biomarker results, every scan report in date order, the drainage record, and the current medication list including steroid doses. That folder is what a second opinion actually runs on, and it is what makes a 45-minute consultation useful instead of a repeat of the history you have already given four times.

The question underneath this page — is this the cancer growing, or is this inflammation from the treatment — comes up in other cancers too, and the answer is shaped by where the disease sits. These pages cover the same reasoning elsewhere, and how immunotherapy is planned and given across our centres.

• Melanoma Brain Metastases and Immunotherapy — the same is-it-swelling-or-growth problem, in the place where getting the answer wrong matters most.
• Immunotherapy for Squamous and Basal Cell Skin Cancers — useful for seeing how eligibility is decided when the tumour is easy to sample and easy to watch.
• Immunotherapy for Thyroid and Salivary Gland Cancers — a clear example of why a treatment established in one cancer does not transfer automatically to another.
• Immunotherapy at CION Cancer Clinics — how immunotherapy is planned by the tumour board, given as day care and monitored across our centres.

Bring the Scan, the Fluid Report and the Biomarker Report

Our tumour board reads them together — medical, surgical and radiation oncology in one room — before anything is proposed to you.